title: HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome.
abstract: OBJECTIVE
  To evaluate morbidity and mortality rates associated with the use of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) after optimal cytoreduction (CRS) in a large single-institutional series of platinum-sensitive recurrent ovarian cancer patients. Moreover, disease free (DFS) and overall survival (OS) of previously studied patients have been assessed after a longer follow-up period.
  
  
  METHODS
  From May 2005 to October 2010, recurrent ovarian cancer patients with a platinum-free interval of at least 6 months have been prospectively enrolled in a protocol of CRS plus HIPEC with oxaplatinum (460 mg/m(2)) heated to 41.5 °C for 30 min, followed by 6 cycles of systemic chemotherapy with taxotere 75 mg/m(2) and oxaliplatin 100 mg/m(2).
  
  
  RESULTS
  Forty-one patients experienced 43 procedures (CRS+HIPEC). An optimal cytoreduction was achieved in all cases (CC-0 95.3%; CC-1 4.7%). A complication rate of 34.8% was registered, with no case of intraoperative death or within 30 days after surgery. Survival curves have been calculated in a group of 25 patients with a minimum follow-up of 18 months, obtaining a median DFS and OS of 24 (range 6-60) and 38 months (range 18-60), respectively.
  
  
  CONCLUSIONS
  In recurrent platinum-sensitive ovarian cancer patients, the use of CRS plus HIPEC represents a safe treatment, able to significantly influence the survival rates compared to chemotherapy alone or surgery plus standard chemotherapy.
authors.affiliation: Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy. anna.fagotti@rm.unicatt.it
authors.forename: Anna
authors.initials: A
authors.lastname: Fagotti
authors.forename: Barbara
authors.initials: B
authors.lastname: Costantini
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Vizzielli
authors.forename: Federica
authors.initials: F
authors.lastname: Perelli
authors.forename: Alfredo
authors.initials: A
authors.lastname: Ercoli
authors.forename: Valerio
authors.initials: V
authors.lastname: Gallotta
authors.forename: Giovanni
authors.initials: G
authors.lastname: Scambia
authors.forename: Francesco
authors.initials: F
authors.lastname: Fanfani
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007274:Injections, Intraperitoneal; D008875:Middle Aged; D009017:Morbidity; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D010534:Peritoneal Neoplasms / Q000628:therapy*; D016896:Treatment Outcome